Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App
07 Dec 2023
Clinical Study
LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS). The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app.
For this study two new tailored treatment-specific versions of OWise have been developed to support UK patients recently prescribed with one of the two treatments within their licenced indications. The study, called RELATE-2, evaluates the experience of patients treated with TDX-d or olaparib while using the OWise treatment-specific modules.
Being led by an international team of clinical researchers, the study's Principal Investigator Dr. Sophie McGrath, a Consultant Medical Oncologist at the Royal Marsden Foundation Trust, commented, "RELATE-2 represents a new way to assess patient experiences in the real world, using a widely available, clinically-validated, cancer patient support app. I'm looking forward to gaining a detailed understanding of how patients experience the use of new treatment-specific support apps countrywide and within specific patient groups."
Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research. With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support. Also, OWise enables patients to directly consent and contribute to clinical research all within the app. OWise is designed to empower patients whilst delivering insights that can help reshape patient care."
The RELATE-2 poster presented by Principal Investigator Dr. Sophie McGrath at the 2023 San Antonio Breast Cancer Symposium can be accessed here: https://pxhealthcare.com/cms/wp-content/uploads/RELATE-2-SABCS-POSTER.pdf
For more information about OWise please visit https://owise.uk
Access Notes here: https://pxhealthcare.com/relate-2-notes
SOURCE PRNewswire - Sales
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.